Cardiff Oncology Inc. Revenue 2011–2025
Cardiff Oncology Inc. annual/quarterly revenue history and growth rate from 2011 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Cardiff Oncology Inc. revenue for the quarter ending March 31, 2026 was 41000, a 62.39% decrease year-over-year.
- Cardiff Oncology Inc. revenue for the twelve months ending March 31, 2026 was 391000, a 41.99% decrease year-over-year.
- Cardiff Oncology Inc. annual revenue for 2025 was 593000, a 13.18% decrease from 2024.
- Cardiff Oncology Inc. annual revenue for 2024 was 683000, a 39.96% increase from 2023.
- Cardiff Oncology Inc. annual revenue for 2023 was 488000, a 26.42% increase from 2022.
- Cardiff Oncology Inc. annual revenue for 2022 was 386000.
Cardiff Oncology Inc. (CRDF) — Frequently Asked Questions
Cardiff Oncology Inc. (CRDF) is a publicly traded US company. It has a market capitalization of $107M. In fiscal 2025 it reported revenue of $593,000 and net income of -$46M. Explore CRDF's stock price, financial statements, earnings history, margins and key ratios below.
What is Cardiff Oncology Inc.'s market cap?
Cardiff Oncology Inc. (CRDF) has a market capitalization of $107M.
What is the CRDF stock price?
CRDF trades at $1.59 (+7.77% on the day).
How much revenue does Cardiff Oncology Inc. make?
Cardiff Oncology Inc. reported revenue of $593,000 in fiscal 2025.
Is CRDF profitable?
In fiscal 2025, Cardiff Oncology Inc. reported net income of -$46M.